Browse the evidence

There is no one-size-fits-all approach to dietary recommendations for the management and treatment of chronic diseases such as obesity.

Practitioners should consider individualized dietary recommendations rather than a standard approach.

Twenty percent (n = 24) of the five-year completers achieved remission from type 2 diabetes.

Practitioners can consider very low carbohydrate diets as a viable option for achieving diabetes remission.

Tirzepatide is an efficacious and safe agent for the treatment of Type 2 Diabetes Mellitus (T2DM).

Practitioners can consider tirzepatide as a treatment option for managing T2DM.

Tirzepatide treatment resulted in a significant decrease of bodyweight compared with the vehicle treatment.

Tirzepatide may be effective for weight management in obese populations.

Tirzepatide treatment significantly decreased serum glucose levels after fasting and improved glucose tolerance compared with semaglutide treatment.

Tirzepatide may offer better glycemic control than semaglutide in obese individuals.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT did not specifically improve menstrual frequency, overall menstrual frequency improved over time.

More participants became pregnant in the low-volume HIT (LV-HIT) group compared to the control group.

This indicates that low-volume HIT may have a positive effect on fertility in women with PCOS.

There is no single mode of physical activity that is superior for weight loss or prevention of weight gain.

Advise clients that various forms of physical activity can be effective for weight management, and they should choose what they enjoy.

All exercise bouts increased mRNA expression of MYOD1 and MYF6 over time.

Engaging in exercise can enhance the expression of key myogenic factors involved in muscle growth.

Factors linked to greater weight loss on liraglutide include being female, not having diabetes, having relatively high baseline weight, and losing at least 4% of initial weight after 16 weeks of treatment.

Healthcare providers should consider these factors when predicting weight loss outcomes for patients on liraglutide.

Baseline body mass index, race, and age seem less relevant for predicting weight-loss response to liraglutide.

Providers may deprioritize these factors when assessing weight loss potential with liraglutide.

Preoperative semaglutide use in patients with type II diabetes mellitus undergoing arthroscopic rotator cuff repair was associated with a lower incidence of any adverse events (11.0% vs 27.4%), severe adverse events (3.5% vs 10.5%), and minor adverse events (8.5% vs 22.0%) within 90 days post-surgery.

Practitioners may consider semaglutide as a beneficial preoperative intervention to reduce postoperative complications in diabetic patients.

Patients not using semaglutide had a greater odds ratio of experiencing any adverse events (3.65) and severe adverse events (3.62) compared to those using semaglutide.

Highlighting the importance of semaglutide in reducing the risk of complications may guide preoperative decisions.

Patients not using semaglutide had a higher 2-year rotator cuff retear rate (18.3% vs 12.5%) compared to those using semaglutide.

This finding suggests that semaglutide may improve long-term surgical outcomes in diabetic patients.

Broad changes in the inflammatory proteome were observed among the study cohort with initial weight loss of ≈8 kg from a median 94 kg at study entry.

Practitioners should consider the role of inflammatory proteins in weight loss and maintenance strategies.

Several of the observed protein associations were also linked to prevalent obesity in the Framingham Heart Study.

Understanding these associations may inform obesity prevention strategies.

Visceral obesity is correlated with cardiometabolic diseases and higher mortality.

Monitoring visceral fat levels can be crucial for assessing mortality risk.

PGDP levels at the 3-month visit were positively correlated with improvements in fat mass, glycaemia, lipaemia, and liver function.

Monitoring PGDP levels may provide insights into metabolic improvements in patients undergoing treatment.

CLA supplementation altered 57 metabolites enriched in lipids/lipid-like molecules compared to placebo.

CLA supplementation may lead to significant changes in lipid metabolism.

Baseline metabolite profiling enhanced prediction accuracy for CLA-induced body composition benefits.

Practitioners can use baseline metabolite profiles to better predict individual responses to CLA supplementation.

Gastric motor functions play a significant role in the development of satiation and satiety, impacting weight change.

Understanding gastric functions can help in designing effective weight loss interventions.

Pharmacological agents like liraglutide and dual agonists contribute to weight loss by retarding gastric emptying.

Incorporating GLP-1 agonists may enhance weight loss strategies.

Bariatric surgery and endoscopic gastroplasty alter gastric emptying and incretin responses in markedly divergent manners.

Choosing between surgical options may depend on their differing impacts on gastric function.

Physical activity and exercise training modify the biological effects of accelerated aging considerably.

Incorporating regular physical activity and exercise can significantly mitigate the effects of aging on cardiovascular health.